DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tasigna (Nilotinib) - Published Studies

 
 



Tasigna Related Published Studies

Well-designed clinical trials related to Tasigna (Nilotinib)

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. [2011.09]

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. [2011.06]

Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. [2011.05]

Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia. [2011.02]

Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. [2011]

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. [2010.06.17]

Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. [2010.02]

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. [2010.02]

Well-designed clinical trials possibly related to Tasigna (Nilotinib)

Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. [2010.11]

Other research related to Tasigna (Nilotinib)

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. [2012]

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. [2012]

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. [2012]

Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. [2011.07]

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. [2011.07]

Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen. [2011.06.16]

[Nilotinib as a second-line treatment for chronic myeloid leukemia]. [2011.06]

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. [2011.05.26]

Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report. [2011.05]

Preclinical evaluation of potential nilotinib cardiotoxicity. [2011.05]

Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis. [2011.04.15]

Nilotinib: a novel, selective tyrosine kinase inhibitor. [2011.04]

Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors. [2011.04]

Clinical experience to date with nilotinib in gastrointestinal stromal tumors. [2011.04]

Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. [2011.03]

Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene. [2011.02]

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. [2011.01.27]

The expanding role of nilotinib in chronic myeloid leukemia. [2011.01]

Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males. [2011]

Effects of yogurt and applesauce on the oral bioavailability of nilotinib in healthy volunteers. [2011]

Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. [2011]

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. [2010.12]

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. [2010.11.26]

[Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)] [2010.08.01]

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. [2010.06.15]

Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. [2010.06]

Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model. [2010.05]

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. [2010.04]

Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase. [2010.04]

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. [2010.04]

Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. [2010.03]

Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment. [2010.03]

Extended kinase profile and properties of the protein kinase inhibitor nilotinib. [2010.03]

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. [2010.01.20]

Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse. [2010]

Nilotinib. [2010]

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. [2010]

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. [2009.09.15]

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. [2009.09.01]

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. [2009.09]

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. [2009.07.15]

Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL. [2009.06]

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. [2009.06]

Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. [2009.01]

Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report. [2009]

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. [2009]

Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. [2008.11]

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. [2008.11]

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. [2008.10]

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. [2008.09.01]

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. [2008.08.01]

Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. [2008.07]

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. [2008.07]

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. [2008.06]

Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. [2008.05]

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. [2008.04]

Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells. [2008.03]

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. [2008.02.15]

Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. [2008]

Nilotinib. [2008]

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. [2007.12.01]

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. [2007.11.15]

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. [2007.11]

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. [2007.10.25]

Nilotinib therapy in chronic myelogenous leukemia. [2007.10]

Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. [2007.08]

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. [2007.07]

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. [2007.06.01]

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. [2007.05.01]

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. [2007.03.01]

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. [2007.01.15]

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. [2006.10.01]

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). [2006.08.15]

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. [2006.06.19]

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. [2006.06.15]

Other possibly related research studies

Management of patients with resistant or refractory chronic myelogenous leukemia. [2008.04.15]

Flying under the radar: the new wave of BCR-ABL inhibitors. [2007.10]

[Novel medical treatment modalities in hematology] [2008.06.09]

Current status of therapy for chronic myeloid leukemia: a review of drug development. [2008.06]

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. [2008.02]

Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. [2008.06]

Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders. [2008.04]

Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. [2008.06]

Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. [2008.04]

[Research Advance on Molecular Genetics of CML Blast Crisis - Review.] [2008.02]

[Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis] [2007]

Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. [2008.08]

[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications] [2008.01.01]

Treatment options in imatinib-resistant chronic myelogenous leukemia. [2008.02]

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. [2008.04.01]

An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. [2008.06]

Targeted therapy in chronic myeloid leukemia. [2008.01]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012